This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Ariad Pharma: The Contrarian Long Thesis

Iclusig may find use in other cancers and '113 is better than the market believes.

Cell Therapeutics: Addicted to Reverse Stock Splits

Through four reverse stock splits, Cell Therapeutics has lost 99% of its value.

Programmed Insider Buying? Yes, at Insmed and United Therapeutics

Instead of selling stock whenever the wind blows, biotech execs should be buying.

Genta: 1998-2012
Genta: 1998-2012

10/25/12 - 07:00 AM EDT

The strange but true tale of a beleaguered, bankrupt biotech firm with 100 quadrillion shares outstanding.

Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data

How best to invest in the next important clinical trial catalyst facing Celgene.

Page 1 of 1
< Previous
Next >
Top Rated Stocks Top Rated Funds Top Rated ETFs